Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Michigan State University

Neither a doctor nor a teaching hospital

Research payments

$1,518,205

362 payments

Through program year 2025, Michigan State University is reported as receiving $1,518,205 in research payments, across 362 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $79,121 24
2024 Research $128,146 53
2023 Research $114,664 23
2022 Research $262,915 28
2021 Research $208,273 44
2020 Research $279,714 101
2019 Research $445,371 89

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $315,122 23 payments
  2. Ucb SA $211,051 12 payments
  3. Bioverativ Therapeutics Inc. $178,226 83 payments
  4. EMD Serono, Inc. $155,456 29 payments
  5. Genentech, Inc. $122,351 30 payments
  6. H. Lundbeck A S $95,868 50 payments
  7. AbbVie, Inc. $78,989 21 payments
  8. Argenx US, Inc. $59,054 28 payments
  9. GlaxoSmithKline, LLC. $43,023 7 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $32,319 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia $142,945 1 payment
  2. Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis $140,257 9 payments
  3. An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A $93,873 45 payments
  4. Emr 100070-001 $76,535 18 payments
  5. A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. $74,721 5 payments
  6. Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis $70,794 3 payments
  7. SC Proof of Efficacy Study $64,426 17 payments
  8. A Phase 3, 12 Month, Open Label Study of Lasmiditan in Pediatric Patients With Migraine Pioneer Peds2 $60,885 5 payments
  9. Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $59,580 5 payments
  10. A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy $59,054 28 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $4,219 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record